Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

42.64 +1.40 (+3.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,080,213
Open 41.31
Bid (Size) 41.80 (1)
Ask (Size) 43.35 (1)
Prev. Close 41.24
Today's Range 41.01 - 42.96
52wk Range 29.16 - 43.62
Shares Outstanding 53,145,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Clover Health, Surgery Partners, Illumina, Bruker, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy
SUPN Q2 Deep Dive: Growth Drivers Shift to New Portfolio as Legacy Products Fade
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2025 results topping the market’s revenue expectations, but sales fell by 1.7% year on year to $165.5 million. The... 
Via StockStory

Performance

YTD
+17.0%
+17.0%
1 Month
+25.6%
+25.6%
3 Month
+35.2%
+35.2%
6 Month
+9.4%
+9.4%
1 Year
+26.7%
+26.7%

More News

Read More
1 Momentum Stock for Long-Term Investors and 2 Facing Challenges
Via StockStory
Earnings Scheduled For August 5, 2025
Via Benzinga
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX)
Via StockStory
Topics Artificial Intelligence Intellectual Property
Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today
Via StockStory
Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales
Via StockStory
Supernus Announces Second Quarter 2025 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Supernus Pharmaceuticals (SUPN) Reports Earnings Tomorrow: What To Expect
Via StockStory
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today
Via StockStory
Topics Lawsuit
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Via StockStory
Topics Artificial Intelligence Intellectual Property
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
Why Supernus Pharmaceuticals (SUPN) Shares Are Falling Today
Via StockStory
Topics Artificial Intelligence Lawsuit
SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) - An Undervalued Stock With Strong Fundamentals
Via Chartmill
1 Stock Under $50 with Exciting Potential and 2 to Turn Down
Via StockStory
2 Cash-Heavy Stocks to Own for Decades and 1 to Approach with Caution
Via StockStory
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
From Brodsky & Smith LLC
Via GlobeNewswire
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms
Via Stocktwits
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
From Brodsky & Smith LLC
Via GlobeNewswire
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics
Via Stocktwits
Topics Government
Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal
Via Benzinga
Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million
Via Investor's Business Daily
Topics ETFs

Frequently Asked Questions

Is Supernus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Supernus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Supernus Pharmaceuticals, Inc. - Common Stock trade on?
Supernus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock is SUPN on the Nasdaq Stock Market
What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?
The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 42.64
When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 08/13/25 04:00 PM ET
What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 2.27B
How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?
Supernus Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.